Literature DB >> 20387305

Biochemical markers in Alzheimer's disease clinical trials.

Henrik Zetterberg1, Niklas Mattsson, Les M Shaw, Kaj Blennow.   

Abstract

This article summarizes how biochemical markers may aid in the development of novel treatments that interfere with fundamental pathogenic processes in Alzheimer's disease. Details are given on the potential use of biomarkers in Alzheimer's disease clinical trials as additional inclusion criteria to enrich study populations with participants who really suffer from the disease, as a means to stratify study participants into meaningful subgroups that may benefit differently from the treatment, and as tools to detect desired biochemical effects and undesired side effects of the drug.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20387305     DOI： 10.2217/bmm.09.80

Source DB:  PubMed          Journal:  Biomark Med        ISSN： 1752-0363            Impact factor:   2.851


  9 in total

1.  Visinin-like protein-1: diagnostic and prognostic biomarker in Alzheimer disease.

Authors:  Rawan Tarawneh; Gina D'Angelo; Elizabeth Macy; Chengjie Xiong; Deborah Carter; Nigel J Cairns; Anne M Fagan; Denise Head; Mark A Mintun; Jack H Ladenson; Jin-Moo Lee; John C Morris; David M Holtzman
Journal:  Ann Neurol       Date:  2011-08       Impact factor: 10.422

2.  Development and advanced validation of an optimized method for the quantitation of Aβ42 in human cerebrospinal fluid.

Authors:  Valerie C Cullen; Ross A Fredenburg; Cindy Evans; Phyllis R Conliffe; Michael E Solomon
Journal:  AAPS J       Date:  2012-05-03       Impact factor: 4.009

3.  Emerging area: biomaterials that mimic and exploit protein motion.

Authors:  William L Murphy
Journal:  Soft Matter       Date:  2011-04       Impact factor: 3.679

4.  Using biomarkers to improve detection of Alzheimer's disease.

Authors:  Milton C Biagioni; James E Galvin
Journal:  Neurodegener Dis Manag       Date:  2011-04

5.  Influence of comorbidities in idiopathic normal pressure hydrocephalus - research and clinical care. A report of the ISHCSF task force on comorbidities in INPH.

Authors:  Jan Malm; Neill R Graff-Radford; Masatsune Ishikawa; Bo Kristensen; Ville Leinonen; Etsuro Mori; Brian K Owler; Mats Tullberg; Michael A Williams; Norman R Relkin
Journal:  Fluids Barriers CNS       Date:  2013-06-10

6.  Kynurenic Acid levels in cerebrospinal fluid from patients with Alzheimer's disease or dementia with lewy bodies.

Authors:  Malin Wennström; Henrietta M Nielsen; Funda Orhan; Elisabet Londos; Lennart Minthon; Sophie Erhardt
Journal:  Int J Tryptophan Res       Date:  2014-04-28

7.  NG2 cells, a new trail for Alzheimer's disease mechanisms?

Authors:  Henrietta M Nielsen; Danyal Ek; Una Avdic; Camilla Orbjörn; Oskar Hansson; Robert Veerhuis; Annemieke Jm Rozemuller; Arne Brun; Lennart Minthon; Malin Wennström
Journal:  Acta Neuropathol Commun       Date:  2013-05-09       Impact factor: 7.801

8.  Reduced Levels of ABCA1 Transporter Are Responsible for the Cholesterol Efflux Impairment in β-Amyloid-Induced Reactive Astrocytes: Potential Rescue from Biomimetic HDLs.

Authors:  Giulia Sierri; Roberta Dal Magro; Barbara Vergani; Biagio Eugenio Leone; Beatrice Formicola; Lorenzo Taiarol; Stefano Fagioli; Marcelo Kravicz; Lucio Tremolizzo; Laura Calabresi; Francesca Re
Journal:  Int J Mol Sci       Date:  2021-12-22       Impact factor: 5.923

9.  Biomarkers of Alzheimer's disease in severe obstructive sleep apnea-hypopnea syndrome in the Chinese population.

Authors:  Weili Kong; Yun Zheng; Wei Xu; Hailing Gu; Junhao Wu
Journal:  Eur Arch Otorhinolaryngol       Date:  2020-04-17       Impact factor: 3.236
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.